Mohamed Ismail

Prof. Mohamed Ismail

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
RSRoberto Simone
Roberto Simone
RBRubika Balendra
Rubika Balendra
TMThomas G Moens
Thomas G Moens
EPElisavet Preza
Elisavet Preza
KWKatherine M Wilson
Katherine M Wilson
AIAdrian M Isaacs
Adrian M Isaacs
Intronic GGGGCC repeat expansions in C9orf72 are the most common known cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), which are characterised by degeneration of cortical and motor neurons, respectively. Repeat expansions have been proposed to cause disease by both the repeat RNA forming foci that sequester RNA‐binding proteins and through toxic dipeptide repeat proteins generated by repeat‐associated non‐ATG translation. GGGGCC repeat RNA folds into a G‐quadruplex secondary structure, and we investigated whether targeting this structure is a potential therapeutic strategy. We performed a screen that identified three structurally related small molecules that specifically stabilise GGGGCC repeat G‐quadruplex RNA. We investigated their effect in C9orf72 patient iPSC‐derived motor and cortical neurons and show that they significantly reduce RNA foci burden and the levels of dipeptide repeat proteins. Furthermore, they also reduce dipeptide repeat proteins and improve survival in vivo, in GGGGCC repeat‐expressing Drosophila. Therefore, small molecules that target GGGGCC repeat G‐quadruplexes can ameliorate the two key pathologies associated with C9orf72 FTD/ALS. These data provide proof of principle that targeting GGGGCC repeat G‐quadruplexes has therapeutic potential. Synopsis Small molecules targeting G‐quadruplex GGGGCC repeat RNA are effective at ameliorating disease phenotypes in C9orf72 patient neurons, and in vivo phenotypes in C9orf72 flies. Therefore, targeting expanded GGGGCC RNA could be an effective therapeutic strategy for C9orf72 ALS and FTD. FRET based screen identifies small molecules that specifically bind to C9orf72 repeat RNA G‐quadruplexes. Small molecules reduce RNA foci and dipeptide repeat proteins (DPRs) in C9orf72 patient neurons. G‐quadruplex GGGGCC binding small molecule improves survival and reduces levels of the toxic DPR poly‐GR in C9orf72 flies. Provides proof of principle for targeting GGGGCC RNA G‐quadruplexes in C9orf72 FTD/ALS.

1 March 2007 in Biophysical Chemistry
Verified
Journal Article
Closed access
EWElizabeth W. White
Elizabeth W. White
FTFarial Tanious
Farial Tanious
MIMohamed Ismail
Mohamed Ismail
ARAnthony P. Reszka
Anthony P. Reszka
SNStephen Neidle
Stephen Neidle
WWW. David Wilson
W. David Wilson

1 February 2018 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
IKI.M. Kenawy
I.M. Kenawy
MHM.A.H. Hafez
M.A.H. Hafez
MIMohamed Ismail
Mohamed Ismail
MHM.A. Abdallah Hashem
M.A. Abdallah Hashem

28 May 2004 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MIMohamed Ismail
Mohamed Ismail
RBReto Brun
Reto Brun
TWTanja Wenzler
Tanja Wenzler
FTFarial A. Tanious
Farial A. Tanious
WWW. David Wilson
W. David Wilson
DBDavid W. Boykin
David W. Boykin

1 October 2009 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
TWTanja Wenzler
Tanja Wenzler
DBDavid W. Boykin
David W. Boykin
MIMohamed Ismail
Mohamed Ismail
JHJames Edwin Hall
James Edwin Hall
RTRichard R. Tidwell
Richard R. Tidwell
RBReto Brun
Reto Brun
African sleeping sickness is a fatal parasitic disease, and all drugs currently in use for treatment have strong liabilities. It is essential to find new, effective, and less toxic drugs, ideally with oral application, to control the disease. In this study, the aromatic diamidine DB75 (furamidine) and two aza analogs, DB820 and DB829 (CPD-0801), as well as their methoxyamidine prodrugs and amidoxime metabolites, were evaluated against African trypanosomes. The active parent diamidines showed similar in vitro profiles against different Trypanosoma brucei strains, melarsoprol- and pentamidine-resistant lines, and a P2 transporter knockout strain (AT1KO), with DB75 as the most trypanocidal molecule. In the T. b. rhodesiense strain STIB900 acute mouse model, the aza analogs DB820 and DB829 demonstrated activities superior to that of DB75. The aza prodrugs DB844 and DB868, as well as two metabolites of DB844, were orally more potent in the T. b. brucei strain GVR35 mouse central nervous system (CNS) model than DB289 (pafuramidine maleate). Unexpectedly, the parent diamidine DB829 showed high activity in the mouse CNS model by the intraperitoneal route. In conclusion, DB868 with oral and DB829 with parenteral application are potential candidates for further development of a second-stage African sleeping sickness drug.

27 September 2003 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MIMohamed Ismail
Mohamed Ismail
RBReto Brun
Reto Brun
JEJudy D. Easterbrook
Judy D. Easterbrook
FTFarial A. Tanious
Farial A. Tanious
WWW. David Wilson
W. David Wilson
DBDavid W. Boykin
David W. Boykin